Clinical and Translational Research
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 6, 2022; 10(13): 3989-4019
Published online May 6, 2022. doi: 10.12998/wjcc.v10.i13.3989
Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration
Qing Peng, Li-Yuan Hao, Ying-Lin Guo, Zhi-Qin Zhang, Jing-Min Ji, Yu Xue, Yi-Wei Liu, Jun-Lan Lu, Cai-Ge Li, Xin-Li Shi
Qing Peng, Li-Yuan Hao, Ying-Lin Guo, Zhi-Qin Zhang, Jing-Min Ji, Yu Xue, Yi-Wei Liu, Jun-Lan Lu, Cai-Ge Li, Xin-Li Shi, Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang 050200, Hebei Province, China
Author contributions: Shi XL and Peng Q designed this research and wrote the main manuscript; Hao LY, Guo YL, Zhang ZQ, Ji JM, Xue Y, Liu YW, Lu JL, and Li CG contributed to the analysis and wrote the manuscript in detail; All authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 81873112; Natural Science Foundation of Hebei Province, No. H2020423009; Hundred Outstanding Innovative Talents Support Program of Universities in Hebei Province, No. SLRC2019043; Basic Scientific Research Project of Hebei Provincial Colleges and Universities, No. JTZ2020005; and Scientific and Technological Capability Improvement Project of the Hebei University of Chinese Medicine, No. KTZ2019002.
Conflict-of-interest statement: The authors declare no competing interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xin-Li Shi, PhD, Professor, Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, No. 3 Xing Yuan Lu, Shijiazhuang 050200, Hebei Province, China. sxlsunshine@sina.com
Received: April 21, 2021
Peer-review started: April 21, 2021
First decision: August 8, 2021
Revised: August 17, 2021
Accepted: February 25, 2022
Article in press: February 25, 2022
Published online: May 6, 2022
Processing time: 373 Days and 17.8 Hours
Core Tip

Core Tip: We performed an integrated bioinformatics analysis to assess the influence of solute carrier family 2 member 1 (SLC2A1) and solute carrier family 2 member 2 (SLC2A2) in hepatocellular carcinoma (HCC). This study revealed that SLC2A1 and SLC2A2 are independent therapeutic targets in HCC and that they are correlated with immune infiltration, in addition to being involved in the metabolic reprogramming in HCC.